• Optimizing Storage for LNP-Formulated Self-Replicating RNA V

  2026-07-27

  This article reviews recent advances in storage optimization for lipid nanoparticle (LNP)-formulated self-replicating RNA vaccines, highlighting findings from Kim et al. The study identifies specific buffer and temperature conditions that preserve vaccine integrity and bioactivity, with direct relevance for translational RNA research and development.

• Practical Guidance for Using 740 Y-P as a PI 3-Kinase Activa

  2026-07-27

  740 Y-P offers researchers a potent, cell-permeable PI 3-kinase activator for precise modulation of the PI3K/AKT signaling pathway in cellular and biochemical assays. It is best used in in vitro workflows such as vesicular trafficking research, apoptosis assays, and neuronal cell survival studies. Use in animal models or clinical applications is not recommended due to lack of supporting data.

• Z-YVAD-FMK: Caspase-1 Inhibitor Protocols for Inflammation R

  2026-07-26

  Z-YVAD-FMK empowers researchers to precisely dissect caspase-1-driven cell death and inflammatory signaling, enabling robust apoptosis and pyroptosis assays across diverse models. This guide delivers actionable protocols, troubleshooting strategies, and application insights for maximizing reproducibility with APExBIO’s Z-YVAD-FMK.

• MK-1775: Selective Wee1 Kinase Inhibitor for G2 Checkpoint A

  2026-07-25

  MK-1775 is a highly selective Wee1 kinase inhibitor that abrogates the G2 DNA damage checkpoint and sensitizes p53-deficient tumor cells to DNA-damaging agents. Its potency, selectivity, and defined workflow parameters make it a leading tool for mechanistic cell cycle research.

• A-769662: Precision AMPK Activator for Metabolic Research

  2026-07-24

  A-769662 offers researchers a potent, reversible AMPK activator to dissect energy metabolism, fatty acid synthesis inhibition, and proteasome regulation with nanomolar precision. Its unique dual action and robust in vivo performance make it indispensable for advanced workflows in metabolic syndrome and type 2 diabetes research.

• Comparative Antibacterial Activity: Thienamycin and Cefopera

  2026-07-24

  This article analyzes a foundational comparative study of N-formimidoyl thienamycin (MK0787) and several advanced β-lactam antibiotics, including cefoperazone sodium salt, against clinically relevant resistant bacteria. The findings provide nuanced insights into β-lactamase resistance, bactericidal thresholds, and the differential spectrum of action useful for both assay design and translational research.

• EZ Cap™ EPO mRNA: Optimizing Erythropoietin mRNA for Neurore

  2026-07-23

  EZ Cap™ EPO mRNA (ψUTP) empowers precise, high-yield protein expression in cellular and in vivo models of erythropoiesis and neuroprotection. Its stability, low immunogenicity, and compatibility with advanced delivery systems make it a gold standard for translational mRNA applications.

• Dronedarone (Multaq): Advanced Workflows for AF Research

  2026-07-23

  Dronedarone (Multaq) from APExBIO empowers translational atrial fibrillation research with workflow-ready solubility, multi-channel modulation, and benchmark purity. This guide details enhanced experimental protocols, troubleshooting insights, and actionable data to optimize cardiac arrhythmia pharmacology studies.

• Biohybrid Euglena Microrobots: Multimodal Tumor Targeting Ad

  2026-07-22

  Gong et al. present a magnetically guided biohybrid microrobot system based on Euglena gracilis, offering unprecedented deformability and multimodal locomotion for navigating biological barriers and targeting tumors. Their approach merges the natural flexibility and therapeutic properties of microalgae with synthetic magnetic control, suggesting a new paradigm for adaptive, drug-free cancer therapies.

• AMPK–SQSTM1 Feedback Loop Drives Antioxidant Defense in Tumo

  2026-07-22

  The reference study reveals a novel double-positive feedback loop between AMPK and SQSTM1/p62, which enables dual activation of AMPK and NFE2L2/NRF2 antioxidant pathways under metabolic stress in tumor cells. These findings clarify the interplay between metabolic and oxidative stress adaptation and provide a mechanistic rationale for co-occurring STK11 and KEAP1 mutations in lung cancer, offering new experimental strategies for targeting tumor adaptation.

• Losartan in Hypertension Research: Protocols & Tumor Microen

  2026-07-21

  Losartan’s role as a selective angiotensin II receptor antagonist is expanding beyond cardiovascular models into innovative tumor microenvironment modulation. This article provides actionable protocols, explores advanced applications such as nanocomposite hydrogel delivery, and delivers troubleshooting strategies for maximum reproducibility in hypertension and oncology research.

• Minoxidil Sulphate in Renal Vascular Research: Evidence & Pr

  2026-07-21

  Explore the protocol-critical role of Minoxidil sulphate in advanced renal vascular and potassium channel research. This article provides unique insights on mechanistic assay design, informed by recent cardiovascular literature, for researchers seeking robust, reproducible outcomes.

• Topotecan (SKF104864): Advanced Protocols for Cancer Researc

  2026-07-20

  Topotecan (SKF104864) is a gold-standard topoisomerase I inhibitor enabling apoptosis induction in glioma cells and robust modeling of antitumor activity in pediatric solid tumor assays. This guide delivers actionable workflow enhancements, troubleshooting strategies, and insights from the latest replication stress research to help you maximize data quality and translational relevance.

• Verapamil HCl Targets TXNIP to Modulate Osteoporosis Pathway

  2026-07-20

  This study reveals a novel application for verapamil HCl in osteoporosis by demonstrating its ability to inhibit TXNIP and regulate bone turnover via key signaling axes in osteoclasts and osteoblasts. These findings expand the translational potential of L-type calcium channel blockers beyond cardiovascular disease, offering a mechanistic rationale for their use in bone disease research.

• Kitasamycin Efficacy and Resistance in Swine Dysentery Contr

  2026-07-19

  This study rigorously evaluates kitasamycin’s (leucomycin) efficacy for controlling swine dysentery caused by Brachyspira hyodysenteriae in Australian pig populations. By integrating MIC profiling and resistance genotyping, the research reveals both the promise and limitations of kitasamycin in the face of widespread macrolide resistance, offering critical insights for translational inhibition and antibacterial assay design.

16508 records 1/1101 page Next 12345 下5页 Last page